AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03654781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: professional periodontal treatment
Description: periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
Study NCT02526355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile based intervention
Description: Learning through Play Plus Intervention delivered through mobile phone
Study NCT04242693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile goal-setting intervention
Description: This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
Study NCT02547870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Description: Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
Study NCT02547870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)
Description: Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
Study NCT02547870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged RPV-LA
Description: Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
Study NCT02731625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell training
Description: Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
Study NCT02731625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Army Physical Readiness Training
Description: Army Physical Readiness Training per Army Field Manual 7-22
Study NCT02731625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Army Physical Readiness Training
Description: Army Physical Readiness Training per Army Field Manual 7-22
Study NCT02799784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI
Description: ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
Study NCT02799784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIO/OLO
Description: TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
Study NCT02799784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
Study NCT01363336 — intervention group
Intervention type: DRUG
Intervention: Nifedipine (Adalat CR, BAYA1040)
Description: patients who are administrated with Adalat CR for hypertension
Study NCT02024477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg tablet once daily for 12 weeks
Study NCT02024477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 12 weeks
Study NCT02245464 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT04276636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caltrate Pill
Description: Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
Study NCT01291914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX005
Description: Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
Study NCT01291914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 (Carrier)
Description: Single intra-articular injection
Study NCT00672672 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous platelet gel
Description: Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
Study NCT00672672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous platelet gel
Description: Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
Study NCT03722485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)
Description: Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
Study NCT03722485 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Ointment
Description: Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
Study NCT03698305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5354
Description: Intravenous
Study NCT03698305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study NCT03968744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: Safinamide taken per Os for 12 weeks
Study NCT01341444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Incision Management System
Description: It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
Study NCT01341444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for Surgical Incisions
Description: Sterile 4X4 Non-Penetrable barrier
Study NCT01316809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Patients will start at 120 mg once daily
Study NCT01291914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2 (Diluent)
Description: Single intra-articular injection
Study NCT02157480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .
Description: outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
Study NCT02157480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week
Description: outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
Study NCT03988634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily
Study NCT03988634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily
Study NCT03988634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan matching placebo
Description: Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily
Study NCT03988634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan matching placebo
Description: Valsartan matching placebo was available as tablet form to be taken orally, twice daily
Study NCT00954954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)
Description: Comparison of different types of knee prosthesis
Study NCT00954954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)
Description: Comparison of different types of knee prosthesis
Study NCT04177225 — intervention group
Intervention type: PROCEDURE
Intervention: Trans thoracic Ultrasound Examination
Description: Ultrasound examination of cardiac function before and after induction of general anesthesia.
Study NCT04177225 — intervention group
Intervention type: OTHER
Intervention: Intravenous fluid administration
Description: Intravenous fluids will be administered as a bolus in response to standard clinical indications
Study NCT02496338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program about menopausal health isues
Description: A three sessions raining program about health issues during menopause for spouses of 45-60 years old
Study NCT00082732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Study NCT00082732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Study NCT00082732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic dietary intervention
Study NCT02897479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
Study NCT03375476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: collection of cardiovascular risk scores and intraoperative cardiovascular parameters
Description: collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
Study NCT03375476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac troponin assay
Description: plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
Study NCT03375476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: 12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
Study NCT01287611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse string closure technique
Description: Uterine Kerr incision will be closed with purse string suture
Study NCT01287611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuously locked closure technique
Description: Uterine Kerr incision will be closed with continuously locked suturing
Study NCT01572389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Outcomes through Patient Empowerment (HOPE)
Description: HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
Study NCT01572389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
Study NCT03532308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermented Soy
Description: Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
Study NCT03532308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo compliment to the active intervention with identical packaging and labeling will be used.
Study NCT01645748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
Study NCT01645748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
Study NCT01645748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
Study NCT02768662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104
Study NCT04193501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
Study NCT04193501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking placebo
Study NCT01969019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone, prednisone
Study NCT00906048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin (HR355) and Rifampicin Therapy
Description: Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight \< 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin
Study NCT02277990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TYRX™ Absorbable Antibacterial Envelope
Study NCT04665011 — intervention group
Intervention type: DEVICE
Intervention: Indicor
Description: A simple, non-invasive tool to report pulse response to a Valsalva maneuver
Study NCT04665011 — intervention group
Intervention type: DEVICE
Intervention: Caretaker
Description: non-invasive blood pressure monitor
Study NCT02019628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran Arabinoxylan Compound (RBAC)
Description: Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
Study NCT00881491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Antibiotic Paste
Description: ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
Study NCT00881491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
Study NCT00881491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: standard material providing an apical barrier
Study NCT03997513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Telerehabilitation
Description: The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
Study NCT02904616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile spectrofluorimeter
Study NCT04493125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
Study NCT04493125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03338790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study NCT03338790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Specified dose on specified days
Study NCT03338790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Specified dose on specified days
Study NCT03338790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rucaparib
Description: Specified dose on specified days
Study NCT03338790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Specified dose on specified days
Study NCT02393287 — intervention group
Intervention type: OTHER
Intervention: Eribulin (ReProLine)
Description: this is an observational trial ; there is no intervention
Study NCT04425018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
Study NCT04425018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
Study NCT04425018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
Study NCT04425018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
Study NCT03506308 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LUTONIX 035 Drug Coated Balloon PTA Catheter
Description: All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Study NCT03045848 — intervention group
Intervention type: DEVICE
Intervention: Biofreedom drug-coated stent
Description: BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
Study NCT03569384 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tele Rehab
Description: The intervention group will obtain telerehabilitation
Study NCT03569384 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tele Rehab
Description: The intervention group will obtain telerehabilitation
Study NCT01446484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+CD25+CD127lowFoxP3+ T regulatory cells injection
Description: Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10\^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx